In 2024, Chugai Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Chugai Pharmaceutical has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 51,143a | 47,991a | 50,265a | |
Total Scope 2 | ||||
Market-Based | 3,267a | 3,458a | 11,940a | |
Location-Based | 65,695a | 64,663a | 58,047a | |
Total Scope 3 | 981,329a | 1,141,573a | 2,232,749a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 6.859a | 6.1072a | 5.3036a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Chugai Pharmaceutical amounted to 116,838 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Chugai Pharmaceutical increased by 3.71%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Chugai Pharmaceutical were 51,143 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Chugai Pharmaceutical's Scope 1 emissions have increased by 6.35%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Chugai Pharmaceutical's Scope 1 emissions increased by 6.57%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, Chugai Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 3,267 tCO₂e using the market-based method and 65,695 tCO₂e using the location-based method.a
Since 2019, Chugai Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Chugai Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.ab
Compared to the previous year (2023), Chugai Pharmaceutical's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Chugai Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Chugai Pharmaceutical reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Chugai Pharmaceutical reported 981,329 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Chugai Pharmaceutical includes a breakdown across 10 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Chugai Pharmaceutical reported total Scope 3 emissions of 981,329 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 99.98% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.02% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2019, Chugai Pharmaceutical's Scope 3 emissionshave remained relatively stable, indicating that Chugai Pharmaceutical's emissions have plateaued with no significant change in its value chain footprint.a
Compared to the previous year (2023), Chugai Pharmaceutical's Scope 3 emissions decreased by 14.04%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2024, Chugai Pharmaceutical reported emissions for 10 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Chugai Pharmaceutical's Scope 3 emissions were:a
In 2024, Chugai Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 51,143 tCO₂e and total revenues of USD 7,456 millions. This translates into an emissions intensity of 6.86 tCO₂e per millions USD.a
In 2024, Chugai Pharmaceutical reported a Scope 1 emissions intensity of 6.86 tCO₂e per millions USD. Compared to the peer group median of 5.07, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Chugai Pharmaceutical ranked 16 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Chugai Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Chugai Pharmaceutical reported a total carbon footprint of 1,098,167 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 12.44% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Chugai Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 89.36% of the company's total carbon footprint, followed by Scope 2 emissions at 5.98%.a